Loading...
Telix Pharmaceuticals Limited
TLX.AX•ASX
Healthcare
Biotechnology
A$20.15
A$-0.90(-4.28%)
Telix Pharmaceuticals Limited (TLX.AX) Financial Performance & Income Statement Overview
Review Telix Pharmaceuticals Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
55.85%
↑ 55.85%
Operating Income Growth
58.29%
↑ 58.29%
Net Income Growth
857.95%
↑ 857.95%
Operating Cash Flow Growth
-100.00%
↓ 100.00%
Operating Margin
7.19%
↑ 7.19%
Gross Margin
73.91%
↑ 73.91%
Net Profit Margin
6.63%
↑ 6.63%
ROE
6.42%
↑ 6.42%
ROIC
2.85%
↑ 2.85%
Telix Pharmaceuticals Limited (TLX.AX) Income Statement & Financial Overview
Review Telix Pharmaceuticals Limited's (TLX.AX) income statement with detailed quarterly and annual figures.
| Metric | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|
| Revenue | $188.96M | $281.71M | $220.83M | $136.05M |
| Cost of Revenue | $65.08M | $57.74M | $130.02M | $91.16M |
| Gross Profit | $123.88M | $223.97M | $90.81M | $44.89M |
| Gross Profit Ratio | $0.66 | $0.80 | $0.41 | $0.33 |
| R&D Expenses | $45.78M | $98.40M | $30.45M | $33.01M |
| SG&A Expenses | $64.25M | $105.50M | $28.93M | $21.58M |
| Operating Expenses | $110.13M | $203.90M | $59.37M | $54.59M |
| Total Costs & Expenses | $175.21M | $261.64M | $189.40M | $145.75M |
| Interest Income | $610000.00 | $566000.00 | $453000.00 | $214000.00 |
| Interest Expense | $4.94M | $548000.00 | $442000.00 | $268000.00 |
| Depreciation & Amortization | $2.00M | $3.64M | $3.29M | $2.66M |
| EBITDA | $15.75M | $23.71M | $34.72M | -$7.05M |
| EBITDA Ratio | $0.08 | $0.08 | $0.16 | -$0.05 |
| Operating Income | $13.75M | $20.07M | $31.44M | -$9.70M |
| Operating Income Ratio | $0.07 | $0.07 | $0.14 | -$0.07 |
| Other Income/Expenses (Net) | -$4.61M | -$4.69M | -$43.74M | -$18.21M |
| Income Before Tax | $9.14M | $15.39M | -$12.30M | -$27.92M |
| Income Before Tax Ratio | $0.05 | $0.05 | -$0.06 | -$0.21 |
| Income Tax Expense | -$2.54M | -$4.14M | $2.02M | $5.27M |
| Net Income | $11.68M | $19.53M | -$14.32M | -$33.19M |
| Net Income Ratio | $0.06 | $0.07 | -$0.06 | -$0.24 |
| EPS | $0.03 | $0.06 | -$0.05 | -$0.10 |
| Diluted EPS | $0.03 | $0.06 | -$0.05 | -$0.10 |
| Weighted Avg Shares Outstanding | $334.23M | $323.73M | $317.62M | $316.34M |
| Weighted Avg Shares Outstanding (Diluted) | $350.75M | $323.73M | $317.62M | $316.34M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan